

# Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C77E628E5B72EN.html>

Date: November 2022

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: C77E628E5B72EN

## Abstracts

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22213TDB, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia

(ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Cervical Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Rectal Cancer, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

Furthermore, this report also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)

The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC

2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Overview

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies  
Involved in Therapeutics Development

Carna Biosciences Inc

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Eli Lilly and Co

Lin Bioscience Inc

Millennium Pharmaceuticals Inc

Schrodinger Inc

Takeda Pharmaceutical Co Ltd

Zai Lab Ltd

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles

AS-0141 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LBS-007 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LY-3143921 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SDGR-1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

simurosertib - Drug Profile

Product Description

Mechanism Of Action

History of Events

simurosertib - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDC7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit CDc7 for Oncology - Drug Profile

Product Description

Mechanism Of Action

TQB-3824 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Nov 03, 2022: Schrodinger to present new preclinical data from its CDC7 inhibitor program at American Society Of Hematology 2022 Annual Meeting

Mar 08, 2022: Schrödinger to present new preclinical data from its Wee1 inhibitor program at AACR Annual Meeting 2022

Apr 12, 2021: Schrödinger reports preclinical data on novel, selective CDC7 inhibitors presented at American Association for Cancer Research Annual Meeting

Mar 30, 2021: Schrödinger to host webcast in conjunction with presentation of preclinical data for its CDC7 program at virtual AACR annual meeting

Mar 10, 2021: Schrodinger announces preclinical data for CDC7 program to be presented at AACR Virtual Annual Meeting 2021

Apr 03, 2019: Sierra reports late-breaking SRA141 preclinical data in poster at AACR 2019

Feb 27, 2019: Sierra Oncology announces late-breaking poster presentation at AACR 2019 for SRA141 preclinical data

Nov 13, 2018: Sierra Oncology reports SRA141 preclinical efficacy at EORTC-NCI-AACR symposium

Nov 09, 2018: Successful Completion of IND filing with FDA for SRA141

Apr 24, 2018: Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia

Feb 27, 2018: Sierra Oncology Provides Update on SRA141

Feb 06, 2018: Sierra Oncology to host program update on SRA141 on February 27th in New York

Aug 23, 2017: Cancer Research UK launches trial to test new drug in patients with advanced cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indication, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pipeline by Carna Biosciences Inc, 2022  
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022  
Pipeline by Eli Lilly and Co, 2022  
Pipeline by Lin Bioscience Inc, 2022  
Pipeline by Millennium Pharmaceuticals Inc, 2022  
Pipeline by Schrodinger Inc, 2022  
Pipeline by Takeda Pharmaceutical Co Ltd, 2022  
Pipeline by Zai Lab Ltd, 2022  
Dormant Projects, 2022  
Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022



## I would like to order

Product name: Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C77E628E5B72EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C77E628E5B72EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970